Bristol Myers Squibb: Share Price Growth In 2022 Best For A Decade - But 2023 Could Better It

Nov. 29, 2022 7:30 AM ETBristol-Myers Squibb Company (BMY)16 Comments


  • Bristol Myers Squibb is a pharmaceutical powerhouse after its Celgene acquisition.
  • The company's revenues in 2022 will be down slightly year-on-year as Revlimid sales fall from $12bn to ~$9bn after patent expiry.
  • The company's new product launches will eventually offset these losses and drive top line growth.
  • 9 new products have been launched within the past 2 years all with blockbuster (>$1bn per annum) revenue expectations.
  • I am expecting more strong growth from the company and think there is another 30% upside to the share price, potentially to be realised in 2023.
  • We're currently running a sale at my private investing ideas service, Haggerston BioHealth, where members get access to portfolios, market alerts, real-time chat, and more. Learn More »

2023 Creative idea concept with rocket on blackboard

akinbostanci/iStock via Getty Images

Investment Thesis

At the beginning of December 2021, Bristol Myers Squibb (NYSE:BMY) stock traded at a value of $53 - its lowest price since the stock market crashed in March 2020 in response to the global pandemic. Today it trades at a price

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth. Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.

This article was written by

Edmund Ingham profile picture
Receive regular, detailed analysis focused on biotech and healthcare stocks

I write about Biotech, Pharma and Healthcare stocks and share investment tips. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. I'm on twitter @edmundingham

Disclosure: I/we have a beneficial long position in the shares of BMY, ABBV, GILD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (16)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.